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                                                             ABSTRACT 
INTRODUCTION 
                             Acute kidney injury is associated with increased mortality of 
around 45% to 60%.  Early diagnosis and initiation of  dialysis can prevent 
progression and decrease mortality in patients with acute kidney injury. However, 
serum creatinine , the standard marker to detect AKI demonstrates major 
limitations. In this study, We prospectively evaluated the role of cystatin C in 
detection of AKI and whether it can detect AKI earlier than serum creatinine. 
AIMS AND OBJECTIVES 
1.    To evaluate the role of cystatin-C as a biomarker for the early detection of 
AKI. 
2. To compare the predictive ability of cystatin-C with serum creatinine level 
in early prediction of AKI. 
3. To assess the correlation of cystatin-C level with the severity  and outcome      
of AKI. 
MATERIALS AND METHODS 
    Single Center, prospective observational study  at Thanjavur Medical College. 
60 patients at risk of developing AKI were studied. 
RESULTS 
   Following results were obtained, 
 Cystatin C levels predicts AKI better than serum creatinine level. 
 Cystatin C levels can predict AKI earlier than serum creatinine value. It can 
predict AKI atleast 1 or 2 days earlier than serum creatinine. 
CONCLUSION 
Serum cystatin C is a sensitive bio-marker  for AKI and it  can predict AKI earlier 
than serum creatinine. 
KEY WORDS 
Acute kidney injury, cystatin C, creatinine. 
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                                           INTRODUCTION  
 
                             Acute kidney injury (AKI)
(1)
 is defined as an abrupt  (within 48 hrs)  
reduction in kidney function – a rise in serum creatinine by ≥0.3 mg/ dl , a  
percentage increase in serum creatinine of  ≥50% from baseline , or documented  
oliguria of < 0.5 ml /kg /hr for more than 6 hours. It can be due to many different  
causes. The incidence varies from 5 % in the overall hospital population to 25% in 
 the intensive care unit patients. It is associated with worse clinical outcome
(2)
 and 
 high mortality ranging from 45 % to 60 %. 
  
                     The poor outcome is due to delay in diagnosis and  delay in initiation 
of dialysis. The delay in initiation of dialysis is in part by the lack of a timely and 
accurate biomarker to predict the occurrence of AKI. At present, Scr level and 
urine output are the standard indicatiors of decreased kidney function despite their 
known limitations. They have limited sensitivity and specificity 
(3)
and creatinine 
level change is delayed in response to kidney impairment, thus limiting their 
usefulness in early detection of AKI. Therefore, the need for an accurate and 
timely biomarker to predict AKI development after renal insult is very important. 
                Newer biomarkers like neutrophil gelatinase associated lipocalin 
(NGAL), kidney injury molecule -1(KIM-1), interleukin -18(IL-18) and Cystatin-C 
are being evaluated in a number of studies for their utility in detecting AKI. 
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Among them, cystatin-C is considered to be good biomarker of kidney function 
because, 
1. It is produced at a relatively constant rate and released in to plasma(4). 
2. >99% is filtered by glomeruli . 
3. There is no significant protein binding. 
       Cystatin-C is a 13 kDa endogenous cysteine proteinase inhibitor.  
Numerous studies have evaluated the role of cystatin-C as an endogenous marker 
of kidney function in population at risk of or with chronic kidney disease, showing 
that cystatin-C is superior to the serum creatinine level in the discrimination of 
normal from impaired kidney function. Recently, studies started evaluating the 
diagnostic accuracy of cystatin-C level in predicting AKI. 
                   In this study, we evaluated the role of cystatin-C as an early biomarker 
in predicting AKI in patients at risk of developing AKI. We also compared the 
diagnostic accuracy of cystatin-C with serum creatinine level in predicting AKI 
and also the correlation of cystatin-C level with severity and outcome of AKI is 
studied. 
CLINICAL ANATOMY:- 
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                    Kidneys are paired retroperitoneal organs
(5)
. Each kidney weighs about 
125 gm to 170 gm in adult male and 115gm to 155gm in adult female. It is 
surrounded by a tough fibrous capsule. 
Dimensions:   
                   Length – 11cm to 12cm. 
                   Width – 5 cm to 7.5cm. 
                   Thickness- 2.5cm to 3cm. 
              It is supplied by renal artery which arises directly from the abdominal 
aorta. The renal artery enters through renal pelvis and divides into an anterior 
branch and a posterior branch. 
              The anterior branch gives rise to three segmental or lobar branches that 
supply upper, middle and lower thirds of the anterior surface of the kidney. The 
posterior surface is supplied by the posterior branch. All are end arteries and there 
is no collateral circulation between individual branches. 
Nephron: 
           Nephron is the functional unit of the kidney. About 0.6 × 10
6
 to 1.4 ×10
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nephrons are there in each kidney. Each nephron contains, 
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1. Glomerulus 
2. Proximal tubule 
3. Loop of henle 
4. Distal tubule 
5. Collecting duct 
Glomerulus: 
                It consists of a capillary membrane lined by single layer of endothelial 
cells. It also has a layer of visceral epithelial cells, a parietal layer and a central 
mesangium. Bowman‘s space is the narrow space between the visceral and parietal 
cells. Plasma is filtered through the glomerular capillaries to form an ultra filtrate. 
This is called glomerular filtration. The factors affecting the glomerular filtration 
are
(6)
:        
 Size of the capillary bed 
 Permeability of the capillaries 
 Hydrostatic and osmotic pressure gradient across the capillaries. 
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                 KIDNEY – CROSS SECTION 
 
               BLOOD SUPPLY OF KIDNEY 
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                            NEPHRON 
 
                                    GLOMERULUS 
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                                    REVIEW OF LITERATURE 
HISTORICAL REVIEW OF LITERATURE: 
                               The history of AKI dates back to 17
th
 century. At first the term 
― ischuria ‖ was used to denote retention of urine or suppression of urine output. 
Following that in late 17
th
 century, it is classified into types like ―ischuria 
urethralis, ischuria ureterica, ischuria vesicalis, ischuria renalis‖(7) depending on 
the organ involved.This leads to further improvement in understanding of renal 
diseases. The clinical features and course of ARF was well established by 18
th
 
century. Also by the end of 18
th
 century, the microscopic features , structural 
alterations in acute renal failure was well studied. 
                              In 1941, Bywaters and Beall reported four cases of renal 
impairment due to crush injury. In that they also described the pathological 
changes in kidney and also demonstrated the presence of tubular damage and 
pigmented casts inside the tubular lumen.                              
        During world war I, ‗war nephritis‘ was the term used to denote the acute 
renal failure caused by severe trauma. After that, many experimental studies were 
conducted regarding the volume hemostasis, hemodynamics of shock, kidney 
function and this leads to better understanding of ARF. By 1951, almost complete 
pathogenesis of ARF was established. The term acute renal failure was introduced 
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by Homer W.Smith in the book ― The kidney ; structure & function in health & 
disease‖. 
HISTORICAL MILE STONES :- 
                                  Galen (empty bladder) - (greek, roman) 
                                                           
                           Morgagni, 1760 (Ischuria renalis) - (18
th
 century) 
                                                            
                          Bright, 1888 (Acute Bright‘s disease) - (19th century) 
                                                                 
                 Davies, 1917 ( War nephritis) - (20
th
 century, before world war ) 
                                                                   
       Bywaters and Beall, 1941 (crush syndrome)- (20
th
 century, after world war II) 
                                                             
                                                        Smith, 1951 (ARF) 
                                                  
                                                         ADQI, 2004  (AKI) 
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                         Following that in late 20
th
 century, John P Merril described the 
clinical course of acute renal failure and its management. Also George E Schreiner 
described the treatment of acute renal failure. Williams J Kolfi contributed to the 
treatment by inventing artificial kidney After this, studies focuses on the treatment 
aspects and early diagnosis of ARF. Recently more studies were conducted to 
identify an ideal marker for kidney function. and also ARF in special clinical 
conditions like sepsis, AIDS, malignancies,  following major cardiac surgery is 
extensively studied. 
ACUTE KIDNEY INJURY 
               The term acute kidney injury denotes the impairment of kidney function 
over hours to days, resulting in retention of nitrogenous and other waste products 
and derangements in volume regulation , electrolyte and acid-base homeostasis. 
AKI is not a single disease but, rather, a term for a heterogenous group of 
conditions that have common features like an increase in blood urea nitrogen level, 
an increase in serum creatinine level, and decrease in urine output. 
                   AKI is synonymous with the older term acute renal failure (ARF) and 
replacing the ARF in recent literature. The term AKI was introduced in the 
year2004 by Acute Dialysis Quality Initiative (ADQI)
(8)
.This is because the term 
failure reflects only part of the spectrum of damage to the kidney that occurs 
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clinically. The newer term AKI reflects the fact that the rise in serum creatinine 
does not mean total failure of the kidneys. It is only a dysfunction which may or 
may not lead to failure. And also the term renal is not well understood by the 
general population. Replacing it with the term ‗kidney‘ makes communication with 
the patients and public more easier
(9)
. 
EPIDEMIOLOGY 
                 The prevalence of AKI is increasing in both developing and developed 
countries. In developed countries surgery and trauma are the most common causes 
of AKI accounting for 60% of cases. In developing countries medical disorders 
(30% to 35%), drugs and toxins(18% to 33%),obstetric complications(8% to 10%) 
are the most common causes of AKI
(10)
. In addition to this, in tropical countries 
infections like falciparum malaria, leptospirosis, dengue, AIDS and acute diarrheal 
diseases and snake envenomation also cause AKI. AKI due to the toxicity of herbal 
and non herbal products is also commonly reported in tropical countries. 
ETIOLOGY AND PATHOGENESIS OF AKI 
               The causes of AKI can be divided in to 3 broad categories, 
1.pre renal azotemia 
2.parenchymal disease 
11 
 
3.post renal obstruction 
PRE RENAL AZOTEMIA 
                  It is the most common form of AKI. It involves rise in SCr or blood 
urea nitrogen concentration due to inadequate renal blood flow
(11)
 and 
intraglomerular hydrostatic pressure thereby decreasing glomerular filteration rate. 
It involves no parenchymal damage to the kidneys and it is rapidly reversible once 
intraglomerular  hemodynamics are restored. Prolonged periods of pre renal 
azotemia can lead to ischaemic injury of the tubules which is called as acute 
tubular necrosis(ATN). 
Causes of pre renal azotemia 
1. Hypovolumia 
2. Decreased cardiac output 
3. Decreased effective circulating volume 
 Congestive cardiac failure 
 Liver failure 
4.Impaired renal autoregulation 
 NSAIDs 
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 ACE inhibitors, ARB 
 Cyclosporin 
Pathogenesis of pre renal azotemia: 
                      Normal GFR is maintained by interactions between the renal plasma 
flow and the transcapillary hydraulic pressure gradient which is determined by the 
relative resistence of the afferent and efferent arterioles. Decreased renal perfusion 
is the hallmark of  pre renal azotemia. This will result in number of immediate 
systemic and renal compensatory responses. These responses are mediated by 
angiotensin II, norepinephrine and vasopressin
(12)
. 
                Decrease in renal perfusion results in sympathetic activation releasing 
noradrenaline. This increases the cardiac output and helps in restoration of renal 
perfusion pressure. Peripheral resistence is also increased to maintain blood 
pressure. This can further decrease renal blood flow but is counteracted by other 
intrarenal mechanisms.  
                Sympathetic activation also releases renin. Renin activates the renin-
angiotensin-aldosterone cascade resulting in formation of angiotensin II. 
Angiotensin II preserves GFR by its preferential vasoconstrictive action on the 
efferent arteriole
(13)
. Anti diuretic hormone (ADH) is released from posterior 
13 
 
pituitary in response to hypovolumia. It acts on V1 receptors causing vaso 
constriction , hence increases the blood pressure. 
 Autoregulation
(14)
 is the first line defence of kidney against fluctuations of arterial 
blood pressure. When the renal perfusion decreases, the afferent arteriole senses 
the degree of stretch and thus relaxes. This is called MYOGENIC REFLEX. 
              TUBULO-GLOMERULAR FEEDBACK also plays an important role 
in auto-regulation. Macula densa presenting in the cortical collecting ducts senses 
the decrease in solute delivery to the distal tubules and leads to afferent arteriole 
dilatation by releasing nitric oxide. 
                                           AUTOREGULATION:- 
                                           Decrease in renal perfusion 
                                           
     Renin, angiotensin II                                                   prostaglandins 
 
Increased efferent arteriole tone                               decreased afferent arteriole tone 
 
                                                     Maintained GFR                                         
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           Autoregulation and other intrinsic compensatory mechanisms fails once the 
systolic blood pressure falls below 80 mmhg. At this stage, renal blood flow is not 
maintained even with the afferent arteriolar dilatation. Instead increasing levels of 
angiotensin II results in renal vaso constriction and further decreases the renal 
blood flow. There will be decrease in urine output, increase in blood urea nitrogen 
and plasma creatinine resulting in pre renal azotemia. If this is not reversed soon, it 
may lead to ischaemic acute tubular necrosis.            
               FAILURE OF AUTOREGULATION:- 
                                    Decreased renal perfusion 
 
Renin                                                                                prostaglandins 
Angiotensin II                                      
            ACE inhibitor                                            NSAIDs 
Decreased efferent arteriole tone                          increased afferent arteriole tone 
 
                                                      Reduced GFR 
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RENAL PARENCHYMAL DISEASE (INTRINSIC AKI)  
                                 The most common form of intrinsic AKI is acute tubular 
necrosis. The common causes of ATN are : 
1. Sepsis 
2. Ischaemia 
3. Nephrotoxins – both exogenous and endogenous. 
Sepsis associated AKI: 
                        AKI complicates more than 50 % of cases of severe sepsis and 
increases the risk of death. Most cases of AKI in sepsis occurs in the presence of 
hemodynamic collapse but decrease in GFR can occur even without overt 
hypotension. 
Pathogenesis of sepsis associated AKI: 
 In the early stages of sepsis, there will be generalized arterial dilatation(15,16) 
including efferent arteriole dilatation which is mediated by inflammatory 
cytokines, nitric oxide etc.  This results in decrease in GFR.   
16 
 
 In later stages due to the compensatory activation of sympathetic nervous 
system, renin- angiotensin- aldosterone system, vasopressin, endothelin 
there will be renal vaso constriction leading to reduction in GFR. 
 Cytokines released in sepsis can cause direct damage to endothelial cells 
resulting in micro thrombi. 
 The reactive oxygen species released in sepsis along with the excessive 
neutrophil activation can cause damage to renal tubular cells. 
 
Ischaemic AKI: 
                  Kidneys receive 20 % of the cardiac output
(17)
. Renal outer medulla is 
particularly vulnerable to hypoxia because of the arrangement of blood vessels. S3 
segment of the proximal tubule is metabolically very active and also vulnerable to 
hypoxia. Ischaemic AKI is usually progression of some pre renal condition to a 
stage where compensatory mechanism fails. Excessive levels of angiotensin II , 
endothelin I, catecholamines causes renal vaso constriction overcoming the   
protective effects of nitric oxide and prostaglandins. This results in hypoxia. 
Inflammatory cytokines are released in response to ischaemia and they result in 
increased leucocyte- endothelial adhesion and endothelial injury.  
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                  The damage to tubular cells manifests as disruption of actin 
cytoskeleton, loss of brush border, loss of cellular polarity, loss of cell matrix 
interactions and loss of tight junctions resulting in detachment
(18)
. With further 
injury the cells undergo either necrosis or apoptosis. 
Post-operative AKI: 
                            Ischaemia associated AKI is a common ,serious complication 
following major operation like cardiac surgery with cardiopulmonary bypass, 
vascular procedures with aortic cross clamping
(19)
, intra abdominal procedures. 
Common risk factors for post operative AKI include underlying chronic kidney 
disease, older age, diabetes mellitus, emergency procedures, congestive cardiac 
failure. 
                    The pathophysiology of post-operative AKI following cardiac surgery 
is multifactorial. It includes, 
 Nephrotoxic contrast agents used for cardiac imaging prior to surgery may 
increase the risk of AKI. 
 Longer duration of cardio pulmonary bypass is also a risk factor for AKI. 
 Cardio pulmonary bypass can also results in extra corporeal circuit 
activation of leucocytes and other inflammatory processes resulting in 
hemolysis and pigment nephropathy
(20)
. 
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INTRARENAL HEMODYNAMICS IN ISCHAEMIC AKI:- 
                                               
 
 
                                                                                                            
 
 
 
 
 
                                 IMBALANCE IN VASOACTIVE HORMONES 
                                        INTRARENAL VASOCONSTRICTION 
                                                     MEDULLARY HYPOXIA 
                                                       
ISCHAEMIA OR TOXIN 
EXPOSURE TO THE KIDNEY 
INCREASE    IN  
VASOCONSTRICTORS 
(ANGIOTENSIN II, 
ENDOTHELIN, 
THROMBAXANE, 
ADENOSINE, PAF, 
LEUKOTRIENES). 
DECREASE  IN  
VASODILATORS 
(PGI2,  NITRIC  
OXIDE). 
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                   PATHOPHYSIOLOGY OF ISCHAEMIC AKI 
 
 
                                                                                                                                                
                                                                                                                 
 
 
 
Afferent arteriolar  vasoconstriction                                  ↓ in tubular reabsorption 
Mesangial contraction                                                         tubular obstruction 
                                                                                             Backleak of GF.                                                                
 
Other causes of ischaemic ATN:  
                                other causes of  ischaemic ATN  includes severe burns, acute 
pancreatitis, extensive trauma. The incidence of AKI in patients with burns more 
ISCHAEMIA OR 
TOXIN  EXPOSURE 
HEMODYNAMIC 
CHANGES 
TUBULAR INJURY & 
DYSFUNCTION 
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than 10 % of total body surface area involvement is around 25 %
(21)
. Hypovolumia 
is the main contributing factor for AKI in case of severe burns and acute 
pancreatitis. In addition to that other factors like dysregulated inflammation, 
secondary sepsis may also increase the risk of development of AKI. Rarely 
extensive fluid resuscitation in case of burns, acute pancreatitis, severe trauma can 
result in abdominal compartment syndrome and renal vein compression leading to 
AKI. 
NEPHROTOXINS ASSOCIATED AKI 
                                Various exogenous and endogenous toxins can lead to tubular 
damage and AKI.  
Endogenous toxin associated AKI : 
 Myoglobin – rhabdomyolysis  
 Hemoglobin – intra vascular hemolysis 
 Uric acid and phosphate – tumour lysis 
 Paraproteins – multiple myeloma. 
Exogenous toxin associated AKI: 
 Radiocontrast – contrast nephropathy 
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 Nephrotoxic drugs (aminoglycosides, cisplatin, tenofovir, 
zolendronate.) – tubular injury. 
 Miscellaneous toxins – snake venom,other animal venoms, paraquat, 
copper sulphate poisoning, herbal medicines. 
Kidneys receives around 20 % of total cardiac output. Due to this high blood flow 
the toxin exposure to nephrons is also high. Hence the tubular, interstitial, 
endothelial cells are exposed to high concentration of toxins causing injury to 
them. All these structures of kidney are vulnerable to toxin mediated injury. Risk 
factors associated with nephrotoxin mediated AKI are older age, pre renal 
azotemia, CKD. Hypoalbuminemia increases the free circulating drug 
concentrations and hence increase the risk of AKI. 
Contrast nephropathy:- 
                        The definition of contrast induced nephropathy (CIN)
(22)
 is an 
elevation of SCr > 0.5 mg/dl above base line or increase of SCr > 25 % within 48 
hrs of administration of contrast. The risk of developing CIN is minimal if the 
renal function is normal. It is markedly increased in the presence of pre existing 
CKD and diabetic nephropathy. CIN usually resolves within one week. More 
severe form requiring dialysis occurs in patients with associated risk factors like 
CKD, CCF, Multiple myeloma. The pathogenesis of CIN
(23)
 includes, 
22 
 
1. Hypoxia in the renal outer medulla. 
2. Direct damage or free radical mediated cytotoxic damage to the 
tubules
(24)
. 
3. Precipitation of contrast material in the tubule causing transient 
obstruction. 
Antibiotics and chemo therapeutic agents: 
                    The most common agents associated with AKI are, 
 Aminoglycosides(25)  
 Amphotericin – B(26)  
 Vancomycin 
 Acyclovir 
 Cisplatin, carboplatin 
 Ifosfamide 
 Bevacizumab  
Toxic ingestions: 
                    Ethylene glycol, an anti freeze agent can cause AKI by direct tubular 
injury. The metabolite 2- hydroxyethoxyacetic acid is responsible for tubular 
injury. Melamine, a food adulterant can cause nephrolithiasis and AKI. Chinese 
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herb nephropathy and BALKAN nephropathy are specific types of toxin mediated 
nephropathy caused by medicinal herbs. The toxin identified in medicinal herbs is 
aristolochic acid. 
Endogenous toxins: 
                   It includes myoglobin, hemoglobin, uric acid and myeloma light 
chains. Myoglobin and hemoglobin lead to pigment nephropathy. The pathogenesis 
of pigment nephropathy includes, 
 Vasoconstriction 
 Direct proximal tubular toxicity(27) 
 Mechanical obstruction of the distal nephron lumen due to 
precipitation.   
               Uric acid is released in excessive amount in case of tumour lysis 
syndrome
(28)
 and can cause AKI by precipitating in renal tubules. Myeloma light 
chains can cause AKI either by direct tubular toxicity or by forming obstructive 
intra tubular casts with Tomm horsfall protein
(29)
. 
OTHER CAUSES OF INTRINSIC AKI: 
   Other rare causes can be categorized according to the anatomical site involved. 
 Microvascular causes 
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 Atheroembolic renal disease 
 Malignant hypertension 
 Scleroderma renal crisis 
 Glomerular causes 
 RPGN 
 Tubular causes 
 Crystalline nephropathy 
 Myeloma kidney 
 Interstitial causes 
 Acute interstitial nephritis 
 Infiltrative malignancies 
 Acute pyelonephritis 
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Sloughing of cells, which is responsible for the formation of granular casts, 
is a feature of acute tubular necrosis 
 
Photomicrograph of a renal biopsy specimen shows renal medulla, which is 
composed mainly of renal tubules. Patchy or diffuse denudation of the renal 
tubular cells with loss of brush border is observed, suggesting acute tubular 
necrosis as the cause of acute renal failure. 
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Histopathology of AKI associated with toxins and venoms 
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AKI IN TROPICS – COMMON CAUSES:- 
INFECTIONS PLANT TOXINS POISONS MISCELLANEOUS 
Falciparum malaria 
Leptospirosis 
Typhoid 
Haemorrhagic fevers 
Infective diarrhea 
HIV 
Scrub typhus 
Chlamydia 
Legionnaires disease 
Melioidosis 
Zygomycosis 
Rift valley fever 
Mushroom 
Herbal medicine 
Djenkol beans 
Propolis 
Cleistanthus 
collinus 
Animal poisons 
Snake bites 
Wasp sting 
Bee sting 
Scorpion sting 
Spider bite 
Chemicals 
Copper sulphate 
Ethylene glycol 
Paraquat 
Formic acid 
G6PD deficiency 
Heat stroke 
Natural disasters 
HUS 
Trauma 
Acute cortical 
necrosis 
Surgical AKI 
Obstetric AKI 
 
 
AKI FOLLOWING SNAKE BITE:- 
                   Around 2,00,000 cases of snake bites have been reported in India every 
year. And death due to snake bite is estimated to be around 35,000 to 50,000.                 
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PATHOGENESIS:                            
              Kidney is more prone to snake venom toxicity because of its high blood 
flow. It is commonly seen in bites by snakes belong to viperidae family. AKI in 
snake bite is most commonly due to ATN. But any structure in kidney may be 
affected causing any of the following lesions
(30)
. 
1. Interstitial nephritis 
2. Vasculitis 
3. Mesangiolysis 
4. Glomerulonephritis 
The pathogenesis of AKI following snake bite is multifactorial. It includes, 
1. Direct nephrotoxicity of snake venom 
2. Hypotension, circulatory collapse 
3. Deposition of hemoglobin, myoglobin in renal tubules 
4. Alteration in intrarenal hemodynamics 
5. Injury by the inflammatory cytokines and other mediators. 
 Snake venom can cause direct injury to proximal tubules(31) resulting in 
decrease in GFR and hence can result in AKI. 
 Snake venom can also directly activate the endothelial cells and resulting in 
release of inflammatory cytokines. Also, the enzymes present on snake 
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venom like metalloproteinases initiate inflammation resulting in release of 
cytokines like IL-1, IL-6, activation of classic and alternate pathways of 
complement system
(32)
. This can cause either direct injury or alteration in 
intra renal hemodynamics causing AKI. 
 POST RENAL ACUTE KIDNEY INJURY 
                            Obstructive nephropathy describes any functional or pathologic 
changes in the kidney that result from urinary tract obstruction. 
Causes: 
                           The most common cause in young men is nephrolithiasis
(33)
. In 
older age group, the most common cause is either benign prostate hypertrophy or 
carcinoma of the prostate. In women, pregnancy
(34,35)
 and gynecological tumours
(36)
 
are the most common causes. 
Pathophysiology: 
                          In initial stages of urinary tract obstruction, the intra tubular 
pressure increases. Hence, the net hydrostatic pressure across the glomerular 
capillary wall decreases resulting in reduction in GFR. In later stages, the 
intraglomerular pressure itself decreases due to angiotensin II and thromboxane A2 
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mediated vasoconstriction. In long standing obstruction, the parenchyma atrophies 
and fibrosis and scarring of the tubulointerstitium occurs. 
COMPLICATIONS OF AKI 
                     The common complications are: 
 Uraemia 
 Hypervolumia 
 Hyponatremia 
 Hyperkalemia 
 Metabolic acidosis 
 Hyperphosphatemia and hypocalcemia 
 Bleeding 
 Infections 
 Cardiac complications – arrhythmias, pericarditis, pericardial effusion. 
Some of these complications can be fatal if left untreated. The average mortality 
rate in AKI is from 45 % to 60 %. 
INDICATIONS OF RENAL REPLACEMENT THERAPY IN AKI 
1) BIO-CHEMICAL INDICATIONS 
 Refractory hyperkalemia (>6.5 meq/litre) 
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 Metabolic acidosis (  pH   ≤ 7.10) 
 Electrolyte disturbances (hypercalcemia) 
 Tumour lysis syndrome (hyperuricaemia) 
 Hyperphosphatemia 
2) CLINICAL INDICATIONS 
 Urine output < 0.3 ml /kg for 24 hrs) 
 Absolute anuria for 12 hrs 
 Multiple organ failure 
 Volume overload 
 Pericarditis 
 Uraemic encephalopathy 
 Uraemic bleeding 
    Renal replacement therapy at appropriate time can prevent most of the 
complications and is life saving. Delay in initiation of dialysis is one of the 
important causes for mortality in AKI. This delay is in part due to non availability 
of a single accurate test to diagnose AKI.  
DIAGNOSTIC EVALUATION OF AKI:- 
                            In patients presenting with AKI , detailed history, physical 
examination, urine analysis, review of previous medical records, drug history, 
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laboratory tests, renal ultrasound and at times, a renal biopsy may be sufficient to 
find out the cause of AKI.  
                     Special investigations like ANA, ANCA, anti- GBM, complement 
level, cryoglobins, ASO titre, protein electrophoresis are useful in certain 
conditions to diagnose the cause of AKI. 
                         Before starting treatment AKI must be distinguished from CKD. 
This can be done clinically by eliciting antecedent history of renal disease in the 
past , radiologically using USG abdomen which can assess the renal size. The size 
of the kidneys will be usually smaller (contracted ) in CKD. But in certain chronic 
conditions like diabetes kidney size may be normal. They can be differentiated 
from AKI by using history of renal problem in the past. Also certain clinical 
findings like anaemia, calcium deficiency can point out the cause of renal failure as 
a chronic condition rather than a acute cause. 
          It is important to differentiate AKI from CKD because AKI usually needs 
aggressive treatment and is  often reversible with appropriate treatment. Whereas, 
CKD should be managed in a different way to minimize the complications and to 
improve the life style of the patient. 
                            But some patients may have acute on chronic kidney disease. In 
those patients the differentiation is difficult and they should be managed like AKI. 
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    The following table shows some differentiating features between AKI and CKD  
FEATURE AKI   CKD 
Antecedent history of renal 
disease 
Absent Present 
Prior sustained elevation of 
Creatinine for > 3 months 
Absent Present 
Anaemia Usually absent at 
onset 
Present 
Elevated serum phosporous,         
PTH. 
Decreased serum calcium 
Absent ( in early 
phase) 
Present 
Neuropathy Absent Present 
Band keratopathy Absent Present 
Renal bone disease Absent Present 
Small kidneys on USG Absent Present ( in some diseases 
normal/ large size) 
Tolerance to azotemia, 
acidosis 
Absent Present 
Stability of azotemia Absent(daily rise) Present 
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Once the diagnosis of AKI is established, then the cause of AKI should be 
determined. The following table shows some urine diagnostic indices that can 
differentiate pre renal azotemia from intrinsic AKI. 
DIAGNOSTIC INDEX PRE RENAL AKI INTRINSIC AKI 
Urine Na
+
 concentration 
(meq /litre) 
  <20 >40 
Fractional excretion of Na
+ 
(%) <1 >1 
Urine urea nitrogen / plasma urea 
nitrogen ratio 
>8 <3 
Fractional excretion of urea (%) <35 >50 
Urine osmolality (mOsmol/kg H2O) >500 <250 
BUN /creatinine ratio >20 <10 – 15 
Renal failure index <1 >1 
Urine sediment Normal Granular casts, 
Epithelial cell casts 
 
HISTORY AND PHYSICAL EXAMINATION: 
                  Careful detailed history is very important to establish the cause of AKI. 
It should include, 
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 History regarding urinary symptoms – voiding difficulties, hematuria, 
dysuria, urine output. 
 History of volume overload or volume depletion – peri orbital swelling, 
weight gain, edema suggests volume overload state, whereas vomiting, 
hemorrhage, diarrhea, polyuria suggests volume depletion state. 
 History of any nephrotoxic drug intake like NSAIDs, ACE inhibitors, 
aminoglycosides. And also history of intake of any over the counter 
medications, herbal products should be elicited. 
 Any recent exposure to IV contrast is also important. 
 History of any antecedent infection should be elicited. 
 History of any pre existing illness like hypertension, diabetes, peripheral 
vascular disease is also important to categorise the risk of AKI. 
PHYSICAL EXAMINATION: 
Physical examination is mandatory to assess the volume status of the 
patient. Physical findings like presence of pedal edema, anasarca, distended neck 
veins, presence of S3 or S4 gallop, inspiratory crackles at lung bases suggests a 
volume overload state. Presence of kussumal breathing indicates metabolic 
acidosis. Other systemic signs like arthritis, rash can provide clues regarding other 
rare causes of AKI like vasculitis, SLE and other connective tissue disorders. 
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DIAGNOSTIC TESTS: 
1.URINE ANALYSIS 
      In the evaluation of AKI, urine analysis and microscopic examination for the 
presence of any urinary sediment is very important
(37)
. It not only distinguish pre 
renal azotemia from post renal causes but also distinguish between  tubular, 
glomerular and interstitial causes. 
 TYPE SEDIMENT  
PRE RENAL Bland; hyaline cast. 
 ACUTE TUBULAR NECROSIS Muddy brown granular cast; epithelial 
cell cast 
GLOMERULO NEPHRITIS Dysmorphic RBC; RBC cast 
ACUTE INTERSTITIAL NEPHRITIS Eosinophils; WBC and WBC cast. 
POST RENAL Monomorphic RBC and WBC or 
crystals. 
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WBC CAST: 
 
 
MUDDY BROWN CAST 
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GRANULAR CAST 
 
RBC CAST 
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DYSMORPHIC RBC 
 
 
URIC ACID CRYSTALS 
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BLOOD INVESTIGATIONS: 
            Review of blood counts and screening tets for coagulation abnormalities 
can provide valuable information regarding the cause of AKI. The presence of 
schistocytes in peripheral smear suggests the presence of DIC, HUS, TTP as a 
cause of AKI. The investigation should also include serum electrolytes, BUN, 
creatinine, pH value. 
RADIOLOGIC EVALUATION: 
         Renal ultrasound is very useful in diagnosing urinary tract obstruction and 
hence a post renal cause for AKI. Also in the initial evaluation of any renal failure 
ultrasound gives valuable information regarding renal size, echo texture. This is 
important to distinguish AKI from CKD. 
KIDNEY BIOPSY:  
                Kidney biopsy is not always required in the management of AKI. If the 
cause of AKI is not apparent then it can help in the diagnosis of certain disease like 
RPGN. Also it is important in certain conditions like lupus nephritis to correctly 
classify the disease before starting any immunosuppressive treatment.  
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MARKERS OF KIDNEY FUNCTION:- 
                   At present there is no single marker available that can predict the 
kidney function. Serum creatinine and BUN are commonly used to assess the 
kidney function. 
UREA AND UREA CLEARANCE 
                   Urea elimination by kidney is a complex process. Hence BUN is a less 
useful marker of kidney function plasma level of urea is influenced by many 
factors other than GFR . Non renal causes for elevated BUN level are GIT 
bleeding, steroid use, total parenteral nutrition. Also malnutrition, chronic liver 
disease can cause decrease in BUN level due to reduced production
(38)
.  
CREATININE AS A MARKER FOR KIDNEY FUNCTION:- 
                             Creatinine is a metabolic product of creatine and the major 
sources are skeletal muscles, dietary meat. Daily production of creatinine ranges 
from 20 to 25 mg / kg / day in males and 15 to 20 mg / kg /day in females. 
                            Creatinine is eliminated by both glomerular filtration and 
proximal tubular secretion. In healthy individuals, >90% of creatinine elimination 
is by glomerular filtration and the rest is by tubular secretion. But when renal 
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function starts declining, the proportion of creatinine which is eliminated by 
tubular secretion increases upto 50%
(39)
.
 
Glomerular filtration rate (GFR): 
                               GFR is defined as the sum of the filtration rate of all functional 
nephrons. The normal value is around 125 ml/min/1.73m
2 
for men and 100 
ml/min/1.73m
2
 for women. GFR is measured by the following formula, 
                                    GFR =   U * V / P. 
              Where,     U is the concentration of the substance in urine 
                               P is the concentration of the substance in plasma 
                               V is urine flow rate. 
The substrate used should be biologically inert, freely and completely filtered by 
the glomeruli, neither secreted nor absorbed by tubules, and not degraded by the 
kidneys. 
                       Inulin was once considered gold standard of exogenously 
administered markers of GFR. But, a number of factors like scarcity, high cost, 
problems related to urine collection to determine inulin clearance limits the 
usefulness of inulin as a marker of GFR. Creatinine is routinely used to calculate 
GFR. 
43 
 
Estimation of creatinine clearance & GFR by creatinine based equations: 
                      Cock croft- gault formula, modification of diet in renal disease study 
(MDRD) equation are the two widely used creatinine based equations for the 
estimation of GFR in adult. 
 COCKCROFT – GAULT EQUATION(40): 
   Est. creatinine clearance = (140 – age ) × body weight  ×0.85 (if female) 
                                               
                                                                   72 × plasma creatinine 
 MDRD EQUATION : 
Est. GFR = 170 × (PCr)
-0.999
 × (age)
-0.175 
× (0.762 if female) × (1.180 if 
African American) × (BUN)
-0.170 
× (albumin)
+0.318
. 
Cockcroft- gault and MDRD equations are important as they can underestimate 
GFR with normal renal function and overestimate GFR with severe renal 
dysfunction. 
LIMITATIONS OF CREATINIE AS A MARKER FOR GFR: 
Creatinine based GFR equations tend to over estimate renal function. so, 
when using creatinine to assess renal function the following limitations should be 
considered. 
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1) Creatinine production depends on certain factors of a patient like body 
mass, race, age etc… 
2) The change in plasma creatinine doesnot correlate with decline in 
renal function in a linear fashion. 
3) The changes in creatinine in an individual should be interpreted based 
on the baseline creatinine value. For this a base line normal value is 
essential which is not available in most cases. 
4) Creatinine level can also be altered by substances that interfere with 
the tubular secretion of creatinine. For example, drugs like 
trimethoprim, cimetidine blocks tubular secretion and hence can 
increase creatinine level. 
5) Creatinine is a useful marker of GFR in the steady state only. In acute 
kidney injury it does not correlate with the sudden changes in GFR. 
 
So, changes in serum creatinine level lag several days behind actual changes in 
GFR. Also the alterations in the level of serum creatinine for small changes in GFR 
are not so sensitive or specific. Hence many other low molecular weight serum 
proteins have been investigated as suitable endogenous markers of GFR 
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DETERMINANTS OF SERUM LEVEL OF CREATININE:                
                                            PRODUCTION (P) 
                                                 (cells, tissues) 
                                                                 
                                                Serum level (S)                  
 
                       
                                         Extra renal elimination 
                                                  ( GIT, liver) 
Where U × V denotes renal excretion. 
(ie) the serum levels are determined by the interaction between production, 
excretion of creatinine.  
 
 
 
Production (P)      
(diet) 
9 
  
U × V (kidney) 
GFR 
TS 
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NOVEL BIOMARKERS:- 
                      BUN and creatinine are the biomarkers of kidney function. They rise 
only after a lag period after AKI. Several novel biomarkers are being investigated 
recently to detect AKI in earlier stage. 
MARKER                                               COMMENT 
SSAT SSAT was able to distinguish ARF with tubular injury from ARF 
without ATN 
CYR61 CYR61 is upregulated in kidneys with IRI—able to distinguish 
prerenal from intrarenal ARF 
IL-18 IL-18 elevated in human kidney ATN (native and transplanted 
kidneys) 
NHE3 NHE3 differentiated prerenal from intrarenal ischemic ATN from 
other intrarenal causes of ARF 
KIM-1 Specific for ischemic ARF/ATN when compared with other forms 
of kidney disease 
Gro-α, KC Gro-α correlates well with renal recovery from AKI/DGF in 
transplant, early increase in urine and blood well before rise in 
serum creatinine in ARF models 
NGAL NGAL sensitive, specific and predictive marker of ARF in blood 
and urine of patients after cardiopulmonary bypass 
Actin, IL-6 
and IL-8 
All three markers predicted prolonged ARF following renal 
transplantation in humans 
             CYR61, cysteine-rich protein 61; DGF, delayed graft function; Gro-α, 
human growth-related oncogene-α; IL-6, interleukin-6; IL-8, interleukin-8; IL-18, 
interleukin-18; KC, keratinocyte-derived chemokine;  NHE3, Na
+
/H
+
 exchanger 
isoform 3; SSAT, spermidine/spermine N1-acetyltransferase. 
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 KIM – 1(41) -  kidney injury molecule is a transmembrane protein.it is 
expressed in epithelial cells of proximal convoluted tubules. It is expressed 
only following ischaemic or toxic injury to the epithelial cells. It is not 
expressed in significant level in normal state. So, it can be used as a marker 
for AKI. 
 NGAL(42) – neutrophil gelatinase associated lipocalin is also called as 
lipocalin -2 or siderocalin . it is a protein first detected in granules present in 
neutrophils. It is found to have some tissue protective effects like binding to 
iron siderophore complexes. Following an injury and inflammation, its level 
increases and can be detected both in urine and plasma. The levels of NGAL 
is found to increase within 24 hours of development of AKI in both urine 
and plasma. It is particularly useful in cases of AKI following cardio – 
pulmonary bypass. 
 Certain cytokines like IL-6, IL-8 have also been studied as markers of AKI. 
In cases of AKI following renal transplantation, the levels of these cytokines 
IL-6,  IL-8 are found to be increased in urine. 
 Alanine amino peptidase  
                         It is an enzyme present in brush border of proximal 
convoluted tubules. It can be measured by using calorimetry. 
 Alkaline phosphatase 
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                         It is also present in the brush border of proximal convoluted 
tubules. S1 and S2 segments contains a tissue non specific alkaline 
phosphatase whereas the S3 segment contains tissue specific (ie) intestinal 
alkaline phosphatase. It is also measured by calorimetry. 
    αglutathione S –transferase 
               It is present in the cytoplasm of proximal convoluted tubule cells. It 
is measured by using ELISA and the levels are found to be elevated in AKI 
and also in renal cell carcinoma. 
 Retinol binding protein: 
                This protein is involved in the transport of vitamin A. it is 
produced by hepatocytes. In the kidney, it is filtered by the glomerulus and 
reabsorbed in the proximal tubules. Hence it can be used as a marker of 
tubular dysfunction. It can be measured by using ELISA or nephelometry. 
  Alpha 1 microglobin: 
               It is also synthesized in liver and filtered by glomerulus. And it is 
reabsorbed in proximal tubules. so it can be used as a marker of tubular 
dysfunction. It is measured by using ELISA, nephelometry. 
 Beta 2 microglobin: 
              It is a part of MHC I molecule. So it is expressed by all nucleated 
cells of the body. Since it is filtered by glomerulus and reabsorbed in 
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proximal tubules, it can be used as a marker of tubular dysfunction. It is also 
measured by using ELISA or nephelometry. 
 Clusterin: 
                   It is expressed on dedifferentiated proximal tubular epithelial 
cells. Its levels are increased in rodent models of AKI, polycystic kidney 
disease, renal cell carcinoma. But its use in human beings is not yet fully 
studied. Its levels can be measured by using ELISA. 
 N-acetyl – β – (D) glucosaminidase  (NGA) 
                        It is present in lysosomes of proximal tubular cells. It is 
measured by using calorimetry. 
 Cysteine rich protein (CYR-61) 
                           In cases of ischaemic kidney injury, CYR-61 is induced in 
proximal tubules of kidney and excreted in urine within a time period of 3-6 
hours. It is detected by using WESTERN BLOT method. But there is no 
quantitative method to estimate CYR-61. 
 Osteopontin 
                   This is found to be increased in rodent models of AKI. Nut its 
use in human beings is not yet established. It is detected by using ELISA. 
The levels of osteopontin correlates with the tubulo interstitial  fibrosis and 
inflammation. 
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 Microalbumin: 
                  This is very well studied and is an approved marker to monitor 
progress in patients with chronic kidney disease. Its levels correlate with 
proximal tubular damage. It is measured by using ELISA and immuno 
turbidometry. But it is not much specific to diagnose AKI. 
 Exosomal fetuin – A: 
                           It is an acute phase protein and is synthesized in liver and 
released in to circulation. Its levels in proximal tubule cytoplasm 
corresponds to the degree of injury. Urinary levels of this acute phase 
protein is found to be much higher in ICU patients with AKI compared to 
healthy volunteers and ICU patients without AKI. It is measured by using 
immunoblotting method. 
 Liver fatty acid – binding protein (L-FABP) 
                                             It is present in proximal tubular epithelial cells. 
It is extensively studied as a bio-marker in chronic kidney disease and 
diabetic nephropathy. Its utility in AKI is under study. It can be measured by 
using ELISA. 
  γ  Glutamyl transpeptidase 
                            It is present in brush border of proximal convoluted 
tubules. It is detected by using calorimetry. 
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 Sodium / hydrogen exchanger isoform (NHES) 
                           This is a sodium transporter found in the renal tubular cells. 
Urinary levels of this transporter can be used to discriminate between pre 
renal azotemia and AKI in ICU patients. It is detected by using 
immunoblotting method. 
URINARY BIO-MARKERS:- 
                  There are certain substances in urine which can be used to diagnose 
kidney injury at an earlier stage. 
 Urine NGAL 
          It is significantly increased in patients with ischaemic and nephrotoxic 
AKI. urinary NGAL was the earliest bio-marker to rise in AKI. In cases of 
severe ischaemia, NGAL level can be detectable within 3 hours in the urine. 
Hence, urinary NGAL can be used as an early and sensitive marker for AKI. 
 IL-18(43) 
        Urinary IL-18 is found to have >90% sensitivity and specificity in 
diagnosing established AKI. Its level in urine rises by 4 to 6 hours after AKI 
and peak levels are attained by 12 hours and the levels remain elevated upto 
48 hours.IL-18 can also be used to predict the development of AKI and this 
is still under study. 
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 EGF: 
         EGF level in urine is found to be decreased in the presence of AKI. 
This is because the diseased glomeruli is unable to filter EGF in to urine. 
Once the renal function gets normalized, the levels of EGF in urine begins to 
rise and attains the normal value. Hence EGF level in urine may be used as a 
marker to predict the recovery of renal function. 
 IGF-1 
     In some studies, IGF-1 level in urine is found to be greater in patients 
with AKI than normal subjects and this elevated levels of IGF-1 in urine can 
be used as a marker of renal injury. 
 In AKI developed after renal transplantation, certain chemokines like 
interferon – gamma induced protein of 10 KD (IP-10) , interferon inducible 
T-cell chemoattractant are found to be increased in urine. But these markers 
were not studied in AKI with causes other than renal transplantation. 
 Other markers like, urinary intercellular adhesion molecule-1 (ICAM-1), 
urinary endothelin-1(ET) were under study. 
 Also in patients with septic shock, certain markers can predict the 
development of AKI. These include soluble tumor necrosis factor receptors 
like S-TNF-R1, S-TNF-R2 etc. their levels are fonud to be increased in 
patients who subsequently develop AKI. 
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 Other markers to predict prognosis in AKI: 
                          In patients requiring dialysis support in AKI, plasma 
fibrinogen level was found to be a prognostic factor. Decreased level of 
plasma fibrinogen is associated with increased mortality 
Among these novel biomarkers , cystatin-C have been extensively studied. 
                                                         CYSTATIN- C 
 HISTORY: 
                   History of cystatin C dates back to 1961. In 1961, in patients with renal 
failure, cystatin C was first identified as a trace protein (gamma trace) in CSF and 
urine. The amino acid sequence of cystatin C was first described by Grubb and 
Lofberg. Initially it was found to be increased in patient with renal failure. Its role 
in the measurement of GFR was first demonstrated by Grubb and coworkers in 
1985
(44)
. Following this the role of cystatin C in CKD, AKI has been extensively 
studied. 
              Cystatin- C is a protein that belongs to cystatin super family. Cystatin 
super family includes 3 inhibitory families. Cystatin-C belongs to type 2 cystatin 
family. It is a cysteine proteinase inhibitor. Its molecular weight is 13 kilodaltons. 
All nucleated cells in the body produces cystatin-C at a constant rate. It is found in 
all biological fluids with highest level in semen. Breast milk, saliva, tears also 
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contains high levels of cystatin –C. It is encoded by CST gene which is located in 
short arm of chromosome 20
(45)
. It is a house keeping gene constantly expressed. 
Structure: 
               It is a non glycosylated, basic protein. It structure comprises of a short 
alpha helix and five stranded beta sheet. It also has two disulphide bonds. 
CYSTATIN –C , THE IDEAL MARKER FOR GFR 
1) It is freely, completely filtered by glomerular filtration and there is no 
tubular secretion. 
- Cystatin C is a non- glycosylated protein. Since it doesnot binds 
to plasma proteins it is eliminated only via glomerular filtration. 
2) Constant level in circulation. 
- Cystatin C is produced by all nucleated cells in the body at a 
constant rate
(46)
. This is because the gene regulating cystatin C 
production is a house keeping gene and is constantly expressed. 
And also, the production of cystatin C is not influenced by 
inflammatory processes
(47)
. 
3) Urine cystatin C – as a marker of tubular dysfunction. 
- Cystatin C is rapidly reabsorbed and degraded in renal tubular 
cells. In cases of tubular dysfunction, this is impaired and 
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cystatin C is excreted as such in urine. Hence, cystatin C levels 
in urine can be used as a marker of tubular dysfunction. 
4) Cystatin C is only eliminated by kidney through glomerular filtration. There 
is no extra renal route of excretion. 
 
CYSTATIN C – BETTER MARKER THAN CREATININE AND 
CREATININE CLEARANCE:- 
               Cystatin C level is not affected by  
i. Sex(48) 
ii. Age 
iii. Muscle mass(49) 
iv. Protein intake 
v. Drugs and metabolic factors 
 Serum creatinine levels change according to age. Serum creatinine 
concentration increases steadily with age. Hence the reference value of 
serum creatinine value should be adjusted according to age. But serum 
cystatin c level remains constant after the age of one year. 
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 Serum creatinine level depends on the muscle mass. Persons having more 
muscle mass may have increased serum creatinine level. But cystatin c level 
is independent of muscle mass. 
 Serum creatinine level can also be affected by a diet rich in protein. But 
cystatin c levels is independent of protein intake. 
 Also substances that block tubular secretion may interfere in the 
measurement of serum creatinine. For example, trimethoprim, cimetidine 
can block the tubular secretion of creatinine. This results in false elevation of 
serum creatinine levels. Also drugs like cefoxitin, flucytosine can interfere 
with the measurement of serum creatinine and give falsely high values. 
 In patients with DKA, the presence of acetoacetate(38) in the plasma can be 
falsely detected as creatinine in calorimetry assay and can give falsely high 
creatinine  value. 
 Also certain endocrine conditions like hypo/ hyperthyroidism can interfere 
in plasma creatinine value. But cystatin c measurement is devoid of these 
limitations and hence it is a better marker than serum creatinine level. 
 And also in different laboratories there is no standardization for the 
measurement of serum creatinine. This can cause intralaboratory variation.  
              
LABORATORY MEASUREMENT OF CYSTATIN C: 
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           Cystatin C can be measured by using radio immune assays, fluorescent or 
enzymatic immune assays. latex immune assays using cystatin C conjugated with 
latex particle is found to be superior
(50)
. The two commonly used latex immune 
assays are PETIA – Particle Enhanced Turbidometric Immuno Assay, PENIA- 
Particle Enhanced Nephelometric Immuno Assay. Among these, in 2002 meta 
analysis study, immunonephelometric method is demonstrated to be superior in the 
measurement of cystatin C
(51). Dade Behring‘s automated immunoassay has been 
approved by FDA for cystatin C estimation. 
Reference range for cystatin C :-         
           For adults and children > 1 yr – 0.53 to 0.95 mg / litre. 
Estimation of GFR from serum cystatin C:- 
GFR is estimated from serum cystatin C level by using following formulas: 
  HOEK FORMULA: GFR = - 4.32 +80.35 ×1/ CYSTATIN C 
   LARSSON FORMULA : 77.239 × CYSTATIN C 
– 1.2623. 
 Since these formulas are difficult to use in routine use, cystatin C calculator had 
been developed and using that we can get the GFR by simply entering the value of 
cystatin C. Also some tables with  pre calculated values of GFR for corresponding 
cystatin C value are available .  
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The following table helps in the calculation of GFR from cystatin C :- 
 
 
SERUM CYSTATIN C 
(mg /litre) 
GFR estimated (ml/min) 
0.6 145 
0.7 119 
0.8 99 
0.9 85 
1.0 74 
1.1 65 
1.2 58 
1.3 52 
1.4 47 
1.5-1.6 41 
1.7-1.8 35 
1.9-2.0 30 
2.1-2.3 26 
2.4-2.6 22 
2.7-3.7 18 
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ROLE OF CYSTATIN C IN OTHER CLINICAL CONDITIONS :- 
 Cystatin C and risk of cardiovascular disease and death(52). 
         Increased levels of cystatin C are found to be associated with increased 
risk of several cardiovascular diseases like MI, heart failure, peripheral 
arterial disease and also with increased risk of death. 
 Cystatin C and renal transplantation and acute rejection in adults. 
          Cystatin C has increased sensitivity compared with creatinine for the 
detection of acute reduction in GFR in cases of renal transplantation and 
hence helps in early detection of acute rejection. 
 Cystatin C in cancer chemotherapy 
           Cystatin C is superior to serum creatinine in estimation of kidney 
function in patients with cancer independent of the presence of metastases or 
chemotherapy. 
 Cystatin C and cirrhosis 
            In cirrhosis, due to decreased protein intake, low muscle mass and 
lack of conversion of creatine to creatinine, creatinine clearance is not ideal 
for the measurement of GFR. Hence serum cystatin C can be used to 
measure GFR in patients with cirrhosis. 
 Cystatin C and neurological disorders 
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          Icelandic type of hereditary cerebral amyloid angiopathy is associated 
with mutations in cystatin 3 gene. This condition predisposes to ICH, stoke, 
dementia. Also CST3 gene is implicated in the genesis of Alzheimer‘s 
disease. Cystatin C levels have been reported to be higher in patients with 
Alzheimer‘s disease. 
 Decreased levels of cystatin C have been associated with increased 
incidence of atherosclerosis and aneurysmal lesions of aorta. This is because 
these lesions are due to imbalance between the proteinases and their 
inhibitors. Since cystatin C is a proteinase inhibitor, its deficiency can cause 
increased activity of proteinases leading to damage and atherosclerosis. 
 Likewise in malignancy, decreased levels of cystatin C is found to be 
associated with more invasiveness of the tumor and metastasis. 
 Also the role of cystatin C in demyelinating diseases like multiple sclerosis 
have been studied. But its role still remains controversial. Further studies are 
needed to clarify its role. 
 Other conditions:  
            cystatin C is also found to be associated with age related macular 
degeneration, pre eclampsia etc. 
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                                            AIMS AND OBJECTIVES: 
1. To evaluate the role of cystatin-C as a biomarker for the early detection of 
AKI. 
 
2. To compare the predictive ability of cystatin-C with serum creatinine level 
in early prediction of AKI. 
 
 
3. To assess the correlation of cystatin-C level with the severity of AKI. 
 
4. To assess the correlation of cystatin-C level with the outcome of AKI.  
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                                 MATERIALS AND METHODS: 
 
Setting                                            :     In patients, 
                                                               Thanjavur medical college hospital, 
                                                               Thanjavur. 
 
Ethical committee approval          :     obtained  
 
Design of study                              :    single centre, prospective observational study 
 
Period of study                               :  April 2012 to November 2012 
 
Sample size                                     :  60 patients                           
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                                     SELECTION OF PATIENTS 
 
INCLUSION CRITERIA:  
  Patients at risk of developing AKI. 
EXCLUSION CRITERIA: 
 Patients with diabetes mellitus 
 Patients with systemic hypertension, CAD 
 Patients with CKD 
 Patients with chronic NSAID abuse 
 Patients with native drug intake 
 Chronic smoking, alcoholism. 
METHODOLOGY: 
                   Patients at risk of developing AKI (ie)   history of preceding snake bite, 
ADD, febrile illness with symptoms suggestive of AKI were selected. Patients 
having one or more risk factors for CKD and patients already having CKD are 
excluded. Also patients with history of alcohol abuse and chronic smoking were 
excluded since these can interfere with the measurement of cystatin C.  
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                 Patients social, demographic, economic and medical details were 
recorded in the proforma sheet. Also the history regarding the symptoms of AKI 
like decrease in urine output was recorded and the duration of symptoms (in hours) 
was also recorded. Base line clinical examination of patient was done. Vitals were 
recorded. Baseline investigations done. USG abdomen was done for all patients to 
assess the renal size and texture to rule out CKD. 
               Serum creatinine level and serum cystatin level were measured on the day 
of admission. Then all of them were followed for the development of AKI. Serum 
creatinine was measured daily and development of AKI was assessed with staging 
system for AKI proposed by AKIN group (ie), 
    Stage 1 = rise in serum creatinine ≥ 0.3 mg/dl or ≥ 150 to 200% from baseline. 
    Stage 2 = rise in serum crearrtinine > 200 to 300 % from baseline. 
    Stage 3= rise in serum creatinine >300% from baseline or serum creatinine                                                                  
                    >4mg with an acute rise of atleast 0.5mg/dl. 
 
        The day the AKI criteria was fulfilled according to serum creatinine was 
noted as day -I. We used either the rise in serum creatinine of ≥ 0.3 mg/dl or ≥ 150 
to 200 % from baseline to diagnose AKI.   patients who did not develop AKI 
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served as controls. In controls, serum creatinine was measured for a minimum of 5 
days starting from the enrollment. Also the duration of stay in hospital is noted for 
all patients and the number of dialysis needed for those who developed AKI was 
also recorded. 
STATISTICAL ANALYSIS: 
                         The end point was the day AKI was  detected by serum creatinine 
according to the staging system of AKI given by the AKIN group. And this was 
compared with the day, cystatin C levels were abnormal. Student-t test was applied 
to find out the difference in mean serum cystatin C values of those who developed 
AKI and those who did not developed AKI. 
                                                        RESULTS 
                   Of 60 patients studied, 41 patients developed AKI according to the 
AKIN- staging of AKI , detected by an increase in serum creatinine of ≥ 0.3 mg/dl 
or ≥ 150 to 200% ( table: 1). Among them, for 40 patients the serum cystatin C 
levels were abnormal in day 1 itself. . Only one patient had normal serum cystatin 
C level on day 1 and developed AKI subsequently.( table : 5) 
                But, all 41 patients had normal serum creatinine level on day 1 and the 
day of development of AKI according to serum creatinine level  (day –I ) was 
either day 2 or day 3. ( table:6)          
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Table:1 
DEVELOPMENT OF  
AKI 
NUMBER PERCENTAGE 
YES 41 68.3 
NO 19 31.7 
TOTAL 60 100 
 
 
 
 
 
68.34
31.66
Development of AKI
YES 
NO
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Table:2 
   NUMBER PERCENTAGE 
MALE 29 48.3 
FEMALE 31 51.7 
 
 
 
 
 
 
48.34
51.66
sex
male
female
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Table:3 
DURATION OF SYMPTOMS 
(IN HOURS) 
NUMBER PERCENTAGE 
5 hrs or less 10 16.67 
>5 hours 50 83.33 
Total 60 100 
Table :4 
DURATION OF SYMPTOMS 
( IN HOURS) 
NUMBER PERCENTAGE 
3 2 3.3 
4 4 6.7 
5 4 6.7 
6 16 26.7 
7 10 16.7 
8 12 20.0 
9 5 8.3 
10 7 11.7 
T0TAL 60 100 
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Table :5 
 ABNORMAL 
(ELEVATED) 
NORMAL 
SERUM CYSTATIN C 
(DAY 1) 
40 (97.6) 1 (2.4) 
 
Table :6 
 ABNORMAL 
(ELEVATED) 
NORMAL 
SERUM CREATININE 
DAY-1 
0 (0%) 60 (100%) 
SERUM CREATININE 
DAY-2 
37 (90.2%) 4 (9.8%) 
SERUM CREATININE 
DAY-3 
40 (97.6%) 1 (2.4%) 
SERUM CREATININE 
DAY-4 
40 (97.6%) 1 (2.4%) 
SERUM CREATININE 
DAY-5 
40 (97.6%) 1 (2.4%) 
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                On applying Student T test for independent samples, there is significant 
difference (P value<0.001)   in  mean serum Cystatin values of those who 
developed AKI and who didn‘t develop whereas  there is no difference in  mean 
serum creatinine values (day one)  of those who developed AKI and who didn‘t 
develop. 
 
                                                     DISCUSSION 
                     Our study shows that serum cystatin C performs as a good marker to 
detect AKI. And also serum cystatin C permits detection of development of AKI 
one to two days earlier than the conventional renal function marker serum 
creatinine. Serum cystatin C was found to be elevated within 6 hours of acute renal 
insult. 
                    Serum cystatin C >0.95 mg/litre ie , the above the normal range was 
found to predict the disease course of AKI. Serum cystatin C sensitivity in picking 
up AKI was found to be more than serum creatinine. These finding is of clinical 
importance because early detection of AKI provides time to prevent the 
progression of AKI. It helps to initiate preventive measures earlier and thereby 
helps to reduce mortality associated with AKI. 
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                  Immunonephelometric assay provides rapid, automated measurement of 
cystatin C within 10 minutes. Serum cystatin C estimation by this method is very 
accurate and precise. Its reliability is approved by FDA. Pre analytic conditions 
like clinical storage and freezing and thawing of blood samples and interfering 
substances like bilirubin and triglyceride can affect measurement of serum 
creatinine. But serum cystatin C measurement is independent of above 
disturbances. Serum cystatin C levels reflects even slight change in GFR more 
rapidly when compared to serum creatinine. This may be due to thefact serum 
cystatin C is an ideal marker of glomerular filtration than creatinine. Because using 
serum creatinine as a marker for GFR has certain limitations like tubular secretion, 
influence by age and body mass. Besides this, in a study by Herget – Rosenthal, 
Marggraf G, Husing J and et al
(53), ― early detection of acute renal failure by 
cystatin C‖ , they also found out that, 
      ‗serum cystatin c is a useful detection marker of ARF, and may detect ARF one 
to two days earlier than creatinine‘. 
                   In our study also among the 41 patients who developed AKI, cystatin C 
predicts AKI in 40 patients in day 1 itself. The predictive value is 97.6%. In only 
one patient who developed AKI cystatin C value is normal on day 1. 
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                   On the other hand, among the 41 patients who developed AKI, all had 
normal serum creatinine value on day 1. The predictive value is 0%. On day 2 
serum creatinine value is found to be increased in 37 patients with a predictive 
value of  90.2%. on day 3 40 patients had increased serum creatinine value and the 
predictivity rises to  97.6% reaching that of cystatin C on day 1.  
                        In a study, ― serum cystatin C a superior marker of rapidly reduced 
glomerular filtration after nephrectomy in kidney donors compared to creatinine‖ 
by Hergert Rosenthal S, Pietrick F and et al
(54)
, they found that, 
          ‗serum cystatin c detects rapid GFR decrease one to two days earlier than 
creatinine. Cystatin c is an early and accurate marker to detect rapid GFR 
decreases as in ARF‘.          
                  In the study patient with history of snake bite, ADD, febrile illness and 
at risk of developing AKI were included. During our study the etiology AKI does 
not seems to have any effect on the predictive value of serum cystatin C in AKI. 
Also patient with history of chronic alcoholism, smoking were excluded from the 
study. This was done to ensure that the measurement of serum cystatin C level 
should be accurate and should not be modified by any other factors besides AKI. 
This enhances the usefulness of serum cystatin C as an ideal marker to detect AKI.  
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                 We selected only patients at risk of developing  AKI and also the study 
group were previously normal persons with out any other risk factors for the 
development of AKI.  
                 The efficacy of cystatin C has been studied in many special situations. 
In a study by Carlo Briguari, MD, PhD:, Gabriella Visconti, MD; and et al
(55)
, they 
concluded that,  
         ‗In patients with CKD cystatin c seems to be a reliable marker for the early 
diagnosis and prognosis of contrast induced acute kidney injury‘. 
          In a study by Qiang Li, Jie-yu Fang, Wei- ping Wang and et al
(56)
, they found 
out that, 
           ‗There is renal injury at early stage of shock. Cystatin C is more sensitive 
than serum creatinine in assessing renal function at the early stage of shock‘. 
                Also cystatin C level is found to be a better marker of kidnry function 
than serum creatinine level in ICU patients. In a study by Maryam Nejat, John 
W.pickering and et al
(57)
, they found out that, 
           ‗plasma cystatin c was an effective and earlier surrogate marker of 
decreased renal function than serum creatinine in a general ICU patients‘  
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               Also there is a conflict that the inflammatory process in sepsis can affect 
cystatin c measurement. But in a study by John Martensson, Max Bell and et al
(58)
, 
        ‗the inflammatory response induced by sepsis has no impact on the level of 
cystatin c in plasma during the first week in the ICU‘. 
                 Few other studies have also supported our finding that changes in GFR 
can be predicted more rapidly, accurately by serum cystatin c than serum creatinine 
level. 
       Serum cystatin c values can also be used in patients with chronic kidney 
disease to predict the prognosis. In a study by Carmen A.Peralta, William Mc 
clellan MD, MPH, Neil A.Zakasi MD and et al
(59)
, they found out that 
                   ‗Adding cystatin c to the combination of creatinine and albumin- 
creatinine ratio measures improved the predictive accuracy for all cause mortality 
and end stage renal disease‘. 
 
 
LIMITATIONS AND STRENGTH OF THE STUDY: 
 Thyroid hormones and glucocorticoid levels can affect the serum cystatin c 
level. In our study we did not measured serum T3,T4 levels or serum cortisol 
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level. But neither of our patients had symptoms suggestive of 
hypothyroidism or glucocorticoid deficiency. 
 In our study only patients with normal creatinine level were included. These 
type of patients with initial normal levels of serum creatinine are generally 
given less priority and may left unnoticed until they develop AKI. 
Measuring cystatin C level in these patients may be more beneficial because 
they can be given special attention and the course of AKI can be altered by 
early initiation of preventive measures. 
 Also these findings may not be suitable for patients with acute on chronic 
kidney disease. 
 Also the serum cystatin c level is measured only on day 1. After that only 
serum creatinine levels are measured daily.  
 Also in our study among the 41 patients who developed AKI , 39 recovered 
completely with treatment, dialysis support. Only two died. And those who 
died have been found to have elevated cystatin C level in day 1(>2.2). 
because of the small number (n=2), we cannot determine the correlation 
between the cystatin C level and mortality in AKI.   
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                                            CONCLUSION 
 
 Cystatin C levels predicts AKI better than serum creatinine level. 
 
 Cystatin C levels can predict AKI earlier than serum creatinine value. It can 
predict AKI atleast 1 or 2 days earlier than serum creatinine. 
 
 
 The association of cystatin C levels with mortality can not be assessed 
because of small sample size. Further studies are needed. 
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                                                 ABBREVIATIONS 
1. ACE – Angiotensin converting enzyme 
2. ADH – Anti diuretic hormone 
3. ADD – Acute diarrheal disease 
4. AKI – Acute kidney injury 
5. ANCA – Anti neutrophil cytoplasmic antibody 
6. ANA – Anti nuclear antibody 
7. ARB – Angiotensin receptor blocker 
8. ARF- Acute renal failure 
9. ASO – Anti strepto lysine – O 
10. ATN – Acute tubular necrosis 
11. BUN – Blood urea nitrogen 
12. CAD – Coronary artery disease 
13. CCF – Congestive cardiac failure 
14. CIN – Contrast induced nephropathy 
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15. CKD- Chronic kidney disease 
16. DIC- Disseminated intravascular coagulation 
17. DKA- Diabetic ketoacidosis 
18. EGF – Epidermal growth factor 
19. ELISA- Enzyme linked immunosorbent assay. 
20. FDA – Food and drug administration 
21. GFR- Glomerular filtration rate 
22. HUS- Hemolytic uremic syndrome 
23. ICU- Intensive care unit 
24. IGF-1- Insulin like growth factor -I 
25. KIM-1- Kidney injury molecule-I 
26. MDRD- Modification of diet in renal disease. 
27. MI- Myocardial infarction 
28. NGAL- Neutrophil gelatinase associated lipocalin 
29. NSAID- Non steroidal anti inflammatory drug 
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30. PAF- Platelet activating factor 
31. PTH- Parathyroid hormone 
32. RBC- Red blood corpuscle 
33. RPGN- Rapidly progressive glomerulo nephritis  
34. SCr- Serum creatinine 
35. SLE- Systemic lupus erythematosus 
36. TTP- Thrombotic thrombocytopenic purpura 
37. WBC- White blood corpuscle 
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                                               PROFORMA            
            
Name:                                                           Age:        Years                                    Sex: Male/Female 
Address:                                                       IP No: 
 
 
Occupation:                                                 Date and time of admission: 
                                                                       Date and time of discharge/death: 
                                                                       Duration of inpatient stay: 
 HD  /  PD : 
HISTORY: 
Admitted with c/o: 
 
H/O presenting illness: 
 
 
Past history: DM/HT/CAHD/CKD/NSAID abuse/COPD/NATIVE DRUG INTAKE/ GLOMERULONEPHRITIS 
Personal history: smoker/alcoholic 
Family history: 
Treatment history/ any surgical procedure: 
 
CLINICAL FEATURES: 
Level of consciousness: 
G/E: pallor/icterus/clubbing/cyanosis/pedal edema/skin lesions(purpura,echymosis,rash). 
         Dyspnoeic/ facial puffiness/ anasarca.         JVP: 
Pulse:         / min                BP:         /         mmHg.        RR:     / min.   
 
CARDIOVASCULAR SYSTEM:   S1,S2                , murmur                , pericardial rub       .  
RESPIRATORY SYSTEM:  VBS    , Crackles       
ABDOMEN EXAMINATION: 
CENTRAL NERVOUS SYSTEM: 
 
 
 
 
INVESTIGATIONS: 
 on 
admission  
   /    /2012 
      /      / 2012       /      / 2012      /        /2012                /  / 2012 
Blood urea 
mg% 
     
Serum 
creatinine mg% 
     
Serum Cystatin 
C mg/l 
(duration of 
symptoms) 
     
 
2. Serum electrolytes sodium-         meq/l 
                                   Potassium-         meq/l 
 
3. USG abdomen:   
               Right kidney -       mm*        mm. Echo-                 , CMD-                     . 
               Left kidney  -         mm*        mm.Echo-                  , CMD-                     . 
               IMP: 
 
4.COMPLETE BLOOD COUNT:                                                     5. URINE: 
           Hb:           gm%                                                                                      Albumin - 
           Tc:             cells/cubic mm.                                                                  Sugar  - 
           Dc:  P     % L       % E     %                                                                      Deposits - 
           RBC:                cells/cubic mm. 
           Platelets:                      cells/cubic mm.          
6.ECG: 
7. Chest X-ray : 
TREATMENT GIVEN:                                                                       OUTCOME: 
  
   
 
 
 
 
 
 
 
 
  
 
 
                                       MASTER CHART 
 
 
 
  
 
 
S.NO NAME AGE SEX 
DURATION 
OF 
SYMPTOMS 
Bl.UREA 
Sr.CYSTATIN 
C 
Scr 
D1 
Scr D2 Scr D3 
Scr 
D4 
Scr 
D5 
DI 
NO. OF 
DIALYSIS 
DURATION 
OF STAY 
OUTCOME 
1 RAJAKUMARI 40 2 10 41 1.1 0.6 1.9 3 3.9 5 2 4 15 1 
2 PALANI 45 1 6 42 1.3 0.8 2 2.9 5 5.8 2 5 19 1 
3 RAJENDRAN 58 1 5 40 0.9 0.8 0.8 0.9 0.8 0.7      - 0 5 1 
4 KUPPUSAMY 60 1 6 38 1.2 0.8 1 1.4 2.7 4 3 2 10 1 
5 NATARAJAN 60 1 6 40 1.4 0.7 1.9 3 5.3 7 2 5 20 1 
6 SIVASANKARAN 19 1 6 42 1.1 0.9 1 1.6 3.8 5.2 3 3 11 1 
7 NEELAMEGAM 40 1 4 40 0.7 0.7 0.8 0.9 0.8 0.8 
       
- 
0 5 1 
8 DHANALAKSHMI 42 2 10 41 1.2 0.7 1.9 4 5.5 6 2 4 14 1 
9 SHAHUL HAMED 60 1 4 38 0.89 0.7 0.7 0.8 0.8 0.7 
      
- 
0 5 1 
10 VALAMBAL 50 2 10 40 1.4 0.9 3.1 4 6.9 7.2 2 7 26 1 
11 SHOBANA 13 2 3 40 1.2 0.8 0.9 1.3 3.9 4.6 3 2 11 1 
12 MALLIKA 45 2 3 43 1.3 0.7 2.2 4 5.7 6 2 4 11 1 
13 GUNASEKARAN 60 1 4 38 0.8 0.8 0.8 0.9 0.7 0.8      - 0 5 1 
14 JOHN KENNADY 36 1 4 42 1.3 0.8 3 4.5 6 5.8 2 4 10 1 
15 SAVITHRI 58 2 8 42 1.2 0.7 1.6 3.9 6 7 2 4 12 1 
16 SIVAPRAKASAM 48 1 5 44 1.2 0.7 1.8 4 5.1 6.8 2 3 13 1 
17 MAHALINGAM 30 1 6 40 0.88 0.8 0.7 0.8 0.9 0.7      - 0 6 1 
18 ANANDAN 38 1 8 41 1.5 0.9 1.1 1.9 7.2 6.5 3 6 12 1 
19 RAJAMMAL 58 2 6 40 1.7 0.8 3.7 6 7.3 8 2 7 21 1 
20 POOMANI 50 2 5 40 0.7 0.7 0.8 0.8 0.9 0.7      - 0 5 1 
21 BHAKIYAM 40 2 5 42 1.6 0.7 3 4.9 6 11 2 8 19 1 
22 
MOHAMMED 
HUSAIN 
43 1 6 38 0.8 0.8 0.7 0.9 0.8 0.8      - 0 6 1 
23 RENUKA 32 2 6 40 1.4 0.8 1 1.5 4.8 6.2 3 3 13 1 
24 MARIMUTHU 50 1 7 36 0.77 0.8 0.8 0.7 0.7 0.8     - 0 5 1 
25 KANSUL 24 1 6 40 1.5 0.8 1.9 2.8 4 5.1 2 5 15 1 
26 ANJAN 50 1 6 40 0.85 0.7 0.9 0.9 0.8 0.8      - 0 5 1 
27 NATESAN 60 1 8 45 2.1 0.8 4 7.9 12 15.6 2 10 27 1 
28 YEGAMBAL 50 2 8 41 1.9 0.8 3.2 4.9 7 8.2 2 7 14 1 
29 MARIMUTHU 47 1 7 40 2 0.8 4.4 5.8 6.1 9 2 8 15 1 
30 LATCHAMPOO 40 2 8 45 1.9 0.9 3.2 5 8.9 7.9 2 9 17 1 
31 VADIVEL 32 1 8 38 0.8 0.9 0.8 0.8 0.7 0.8      - 0 5 1 
32 VASANTHA 41 2 6 40 1.9 0.7 1.6 5.8 8 6.8 2 6 18 1 
33 SHOBANA 11 2 8 41 2.1 0.8 4.6 5.3 6.9 10 2 8 20 1 
34 SEETHALA DEVI 4 2 6 40 1.7 0.8 1 4.1 6.2 7 3 6 13 1 
35 ANNAKILI 29 2 7 39 0.82 0.8 0.8 0.9 0.9 0.7      - 0 6 1 
36 SELVAKUMAR 29 1 8 46 2.1 0.8 3.9 5 8.8 9 2 7 18 1 
37 MUTHULAKSHMI 40 2 7 40 0.79 0.7 0.7 0.8 0.9 0.8      - 0 5 1 
38 CHITHRA 30 2 6 40 1.7 0.9 1 2.6 3.8 5.2 3 5 14 1 
39 INDIRA 23 2 8 40 1.8 0.8 1.1 1.9 4.5 7 3 6 12 1 
40 KASINATHAN 40 1 8 42 1.9 0.9 1.1 2.4 5.2 5.4 2 7 10 1 
41 ANJAMMAL 40 2 8 40 0.78 0.8 0.9 0.8 0.9 0.7 
      
- 
0 6 1 
42 VIJAY 14 1 9 46 2.3 0.9 4.1 6 7.9 10 2 9 21 1 
43 JAYALAKSHMI 60 2 10 38 2.1 0.8 2.2 3.9 5.1 8 2 7 20 1 
44 RAJAKUMARI 40 2 6 36 0.81 0.7 0.6 0.8 0.9 0.8       0 5 1 
  
 
 
 
- 
45 MURUGANATHAN 18 1 7 45 1.7 0.9 1 1.8 3 4.4 3 5 12 1 
46 SELVI 28 2 7 42 1.9 0.8 2.1 4 4.9 5.4 2 6 15 1 
47 RADHIKA 35 2 9 34 0.79 0.7 0.6 0.7 0.6 0.7 
      
- 
0 7 1 
48 SENTHILNATHAN 40 1 7 46 1.7 0.7 1.9 3.8 4.1 5.4 2 6 15 1 
49 AYYAMMAL 40 2 6 30 0.69 0.7 0.7 0.7 0.8 0.7 
      
- 
0 8 1 
50 DEVARAJ 45 1 8 42 1.9 0.7 0.9 2.6 4.9 5 3 8 15 1 
51 USHA 50 2 7 45 1.7 0.7 0.8 1 2.2 3.9 3 7 10 1 
52 MALAR 30 2 7 33 0.75 0.6 0.7 0.8 0.7 0.7 
       
- 
0 6 1 
53 SRINIVASAN 42 1 6 45 1.7 0.8 3.9 5.6 5.5 7 2 6 14 1 
54 JAYALAKSHMI 46 2 7 36 0.7 0.8 0.8 0.7 0.7 0.7 
         
- 
0 5 1 
55 KASTHURI 50 2 10 46 2 0.7 2.9 4.8 6.3 6.9 2 8 19 1 
56 JOHN PETER 50 1 9 40 2.1 0.8 3.8 6 8 8.8 2 9 25 1 
57 GANESAN 55 1 9 38 0.85 0.7 0.7 0.8 0.9 0.9 3 0 5 1 
58 THAMBUSAMY 50 1 10 48 2.7 0.8 3.7 5.2 8.8 9.1 2 10 21 2 
59 ANJALAI 50 2 10 46 2.4 0.9 4.3 5.6 8.9 7.8 2 8 20 2 
60 VEMBU 45 2 9 32 0.77 0.8 0.9 0.8 0.8 0.8 
         
- 
0 6 1 
  
 
 
 
 
 
 
 
 
 
 
 
